BREAST CANCER

The risk of progression or death in post-menopausal patients with estrogen receptor-positive locally advanced or metastatic breast cancer was reduced with camizestrant in the SERENA-2 study.

Jamie Brett discusses the similarities and differences between ESR1 mutations and fusions and why they are grouped together.

During a Targeted Oncology case-based roundtable event, Rachel C. Jankowitz, MD, discusses the result of treatment with sacituzumab govitecan in the ASCENT trial of patients with triple-negative breast cancer.

During the 2022 October ASCO Plenary Series, an analysis from the PALLAS trial revealed there to be no invasive disease-free survival benefit derived with palbociclib added to endocrine therapy in ER-positive breast cancer.

The second interim analysis of OlympiA showed olaparib to improve overall survival, invasive-disease-free survival, distant-disease-free survival, and revealed no new safety signals in patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer.

As we identify more targets...there will probably be more and newer, perhaps even better, therapeutics than we have currently, said Dennis J. Slamon, MD.

In an interview with Targeted Oncology, Matthew P. Goetz, MD, discussed these recent data on estrogen receptor mutations in patients with breast cancer. He also provided expert insight on the results of ELAINE-1.

Identifying a number of cancer predisposition genes could help improve upon risk assessment and counseling for ductal carcinoma in situ and contralateral breast cancer.

William J. Gradishar, MD, discusses the choice of adjuvant or neoadjuvant regimens for patients with HER2-positive breast cancer.

During a Targeted Oncology case-based roundtable event, Jennifer M. Matro, MD, discussed the data supporting systemic therapies for treatment of early-stage HER2-positive breast cancer including trastuzumab and pertuzumab.

Despite advances in the treatment of breast cancer, challenges remain, such as the development of resistance to existing therapies, serious adverse events, and suboptimal treatment adherence.

Muhammad Imam, MD, reviews the use of newer antibody-drug conjugates for patients with metastatic breast cancer across subtypes.

The PRESERVE 2 trial evaluating trilaciclib in patients with metastatic breast cancer has finished enrolling patients. Results from the interim analysis of the trial is expected in the second half of 2023.

Frederick Marme, MD, discusses new results from the TROPICS-02 study of sacituzumab govitecan for the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer.

Matthew P. Goetz, MD, discusses recent data on estrogen receptor mutations in patients with breast cancer.

During a case-based roundtable event, Christos Vaklavas, MD moderated a discussion about treatment option for a 48-year-old woman with triple negative breast cancer following adjuvant chemotherapy.

Clinicians use their knowledge of emerging subtypes and biomarkers, which provide a hint at possible outcomes, to select therapy from among the ever-increasing treatment armamentarium.

During a Targeted Oncology case-based roundtable event, Erika P. Hamilton, MD, discussed the choice of first- and second-line therapy for a patient with triple-negative breast cancer following adjuvant chemotherapy.

William J. Gradishar, MD, discusses the questions ongoing studies are looking to answer in the breast cancer space.

Nearly all patients with HR-positive breast cancer are treated with endocrine therapy, yet Black women are 4 times more likely to die of this disease compared with White women.

A patient with estrogen receptor positive, HER2-negative metastatic breast cancer enrolled in the phase 2 ELAINE 1 trial demonstrated a durable complete response when treated with lasofoxifene.

Ribociclib combined with endocrine therapy adds survival benefit when given to patients with hormone receptor–positive/HER2-negative advanced breast cancer with visceral metastases.

Pembrolizumab in the neoadjuvant and adjuvant settings demonstrated similar health-related quality-of-life scores in patients with triple-negative breast cancer when compared with placebo.

Patient-reported outcomes from the DESTINY-Breast04 trial showed a quality-of-life benefit from treatment with trastuzumab deruxtecan compared with physician’s choice of therapy in patients with hormone receptor–positive, HER2-low metastatic breast cancer.

The AMEERA-3 trial failed to meet its primary end point of superior progression-free survival for amcenestrant compared with endocrine therapy in patients with endocrine-resistant, ER-positive advanced breast cancer.

The antibody-drug conjugate sacituzumab govitecan demonstrated superior overall response rate and progression-free survival in patients with breast cancer with limited options due to lack of high HER2 expression.

While lasfoxifene alone did not meet the primary end points that researchers set out for it, they did find that it improves responses in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.

The phase 2 DAWNA-2 trial of dalpiciclib plus letrozole or anastrozole led to a reduced the risk of disease progression vs chemotherapy alone in patients with treatment-naïve, hormone receptor–positive, HER2-negative advanced breast cancer.

Oleclumab plus durvalumab and chemotherapy did not increase clinical benefit rate for patients with advanced triple-negative breast cancer, according to results from the phase 2 SYNERGY trial.

Treatment with sactiuzumab govitecan improved overall survival, objective response rate, duration of response, and overall quality of life vs physician’s choice in the phase 3 TROPiCS-02 study.